Martin Shkreli: Daraprim, $64.6M Order and Wu-Tang Records (2026)
Some links pay us a referral fee; each one says so. Disclosure
Update alert · free
An email when the sec fraud cases and investor recoveries numbers change
When a rate, rule or filing behind this page changes: what changed, the one number that matters, and the source to check it yourself.
Quick answer
In August 2015 a company run by Martin Shkreli bought the old parasite drug Daraprim and, within days, raised its list price from $17.60 to $750 a tablet; a federal court later ordered him to disgorge $64.6 million and banned him from the pharmaceutical industry for life. That is the court's own pre-hike figure of $17.60 (opinion of January 14, 2022). The FTC and the New York Attorney General say $17.50, and the $13.50 that is often repeated appears in none of the documents we read. The $64.6 million is a civil order from the FTC case, 1:20-cv-00706 (S.D.N.Y.), and is separate from his criminal case, 15-cr-637 (E.D.N.Y.), where he was sentenced to 84 months on March 8, 2018 for defrauding hedge fund and Retrophin investors.
Where it stands as of November 20, 2026: the Second Circuit affirmed the civil judgment on January 23, 2024 and the Supreme Court denied review in October 2024. The criminal forfeiture was settled when the United States sold the one-copy Wu-Tang Clan album on July 27, 2021; the Justice Department says the buyer and the price are confidential. On October 13, 2026 the FTC and seven states asked the court to hold him in contempt for trading pharmaceutical stocks, and the plaintiffs' brief says he still owes the full $64.6 million. We found no ruling on that motion.
Key takeaways
- Three different pre-hike prices circulate for the same pill: $17.60 per tablet (the court's finding of the list price, August 11, 2015), $17.50 (FTC and New York Attorney General releases) and $13.50 (repeated in coverage, but in none of the documents we read). All agree on $750 afterwards. At $17.60 the increase is a factor of 42.6 (our arithmetic).
- The $64.6 million was not a fine and it did not go to the FTC. The opinion says the FTC is precluded from seeking disgorgement, so the sum is ordered to the seven plaintiff states. It is the court's estimate of excess profit from October 2018 to December 2020: $67.6 million of lost revenue less $3 million of avoided costs (our arithmetic: $64.6 million), against $130.6 million of actual Daraprim revenue in the period.
- The criminal and SEC cases produced five different money figures: a $75,000 fine, about $388,000 of restitution, a forfeiture the Justice Department puts at $7.3 million at sentencing in March 2018 and about $7.4 million in July 2021, the government's own request of $7,360,450 in November 2017, and the SEC's $1,392,000 civil penalty of February 23, 2022. Victim restitution is about 5 percent of the forfeiture (our arithmetic: $388,000 divided by $7.3 million).
- The Wu-Tang album was a substitute asset. The government's November 30, 2017 motion lists it with $5 million of bail cash and other items; after the Second Circuit upheld the conviction in July 2019, the album was sold and the Justice Department said the payment of the forfeiture was complete. Buyer and price are confidential, so no document we have gives what it fetched.
- Retrophin's own Form 8-K of February 20, 2015 is the company's account of paying for its founder's hedge fund problems: 612,500 shares and $400,000 in consulting agreements, about $2.2 million in cash and 11,000 shares in settlements, a $575,000 payment to the CEO that appears to have been a discretionary bonus, and about $1.2 million of other obligations. The board told investors the 2013 10-K should no longer be relied upon.
- Added up from the documents, the orders against him come to about $73.8 million before any offset (our arithmetic: $75,000 + $388,000 + $7.3 million + $1,392,000 + $64.6 million). The civil figure carries an offset of up to $40 million if the corporate defendants pay, and Vyera's December 2021 settlement is up to $40 million, only $10 million guaranteed. The plaintiffs' October 2026 brief says he still owes the $64.6 million and quotes a 2025 writ saying he owed the SEC penalty plus interest.
CSV · 64 rows
Martin Shkreli: Daraprim pricing, court orders, forfeiture and Retrophin disclosures, 2009-2026
64 rows: Daraprim prices and sales, the disgorgement arithmetic, every money order with its court and date, the forfeiture request by count, and Retrophin's 8-K figures. Source and document on every row.
The story, dated
A hedge fund manager lost his investors' money, told them he had made profits, built a listed drug company, and later bought an old drug at what the court called a considerable premium to its market value. The records below follow the money through three separate cases: a criminal case in Brooklyn about investors, an SEC case about the same conduct, and a civil antitrust case in Manhattan about the price of one pill.
| Date | Event | Document |
|---|---|---|
| 2009 | MSMB Capital hedge fund founded; the 2009 to 2014 period of Count Three begins | USAO EDNY press release, March 2018 |
| December 2012 to September 2014 | Shkreli is Retrophin's CEO | S.D.N.Y. opinion, January 14, 2022 |
| April 2015 | Vyera makes an unsolicited $60 million offer to the owner of the Daraprim rights | S.D.N.Y. opinion |
| August 7, 2015 | Deal closes at $55 million; Daraprim's annual net sales had been roughly $4 million | S.D.N.Y. opinion |
| August 11, 2015 | List price raised from $17.60 to $750 per tablet | S.D.N.Y. opinion |
| December 17, 2015 | SEC files its civil complaint (15-cv-7175, E.D.N.Y.) | SEC Litigation Release 25337 |
| August 4, 2017 | Federal jury convicts him on three counts in 15-cr-637 | S.D.N.Y. opinion, footnote 9 |
| November 30, 2017 | Government asks for $7,360,450 in forfeiture and lists substitute assets, among them the Wu-Tang album | Government motion, Doc. 464 |
| March 8, 2018 | Sentenced to 84 months; $75,000 fine; forfeiture | S.D.N.Y. opinion, footnote 9; USAO EDNY |
| July 2019 | Second Circuit affirms conviction and sentence | USAO EDNY press release, July 27, 2021 |
| January 27, 2020 | FTC and states file the Daraprim antitrust suit (1:20-cv-00706) | S.D.N.Y. opinion |
| March 2020 | First generic version sold in the United States | New York Attorney General release, January 14, 2022 |
| July 27, 2021 | United States sells the sole copy of the Wu-Tang Clan album; forfeiture complete | USAO EDNY press release |
| December 7, 2021 | Vyera and Phoenixus settle: up to $40 million, $10 million guaranteed | FTC press release |
| December 14-22, 2021 | Seven-day bench trial against Shkreli | S.D.N.Y. opinion |
| January 14, 2022 | Opinion: lifetime ban and $64.6 million disgorgement | S.D.N.Y. opinion, Doc. 865 |
| February 4, 2022 | Judgment and permanent injunction entered | Second Circuit summary order |
| February 23, 2022 | SEC final judgment: officer and director bar, $1,392,000 penalty | SEC final judgment, Doc. 55 |
| May 2022 | Released from prison | Plaintiffs' memorandum, October 2026 |
| January 23, 2024 | Second Circuit affirms the civil judgment | FTC statement; Second Circuit order, 22-728 |
| October 2024 | Supreme Court denies certiorari | Plaintiffs' memorandum, October 2026 |
| October 13, 2026 | FTC and seven states move to hold him in civil contempt | FTC press release |
Every money order, from the documents
| Court or agency | Date | Amount | What it is | Status in the documents |
|---|---|---|---|---|
| E.D.N.Y., 15-cr-637 | March 2018 | $75,000 | Criminal fine | Not mentioned again in the records we read |
| E.D.N.Y., 15-cr-637 | March 2018 | $7.3 million (DOJ, 2018); about $7.4 million (DOJ, 2021) | Forfeiture money judgment | DOJ, July 27, 2021: payment of the forfeiture is complete after the album sale |
| E.D.N.Y., 15-cr-637 | March 2018 | About $388,000 | Restitution | Ordered; payment not described in the records we read |
| E.D.N.Y., 15-cv-7175 (SEC) | February 23, 2022 | $1,392,000 | SEC civil penalty, plus a permanent officer and director bar | A writ of garnishment of July 31, 2025, quoted by the plaintiffs, says he owes the penalty plus interest |
| S.D.N.Y., 1:20-cv-00706 (FTC and seven states) | January 14, 2022 | $64.6 million | Disgorgement to the plaintiff states, joint and several with Vyera, with a set-off of up to $40 million paid by the corporate defendants | Affirmed January 23, 2024; the plaintiffs' October 2026 brief says he still owes the full amount |
| S.D.N.Y., 1:20-cv-00706 | December 7, 2021 | Up to $40 million | Vyera and Phoenixus relief ($10 million up front, up to $30 million over 10 years) | Settled; Shkreli was not covered |
| S.D.N.Y., 16-cv-7175 (private civil case) | Receivership order August 16, 2021 | $2,614,930 | A private judgment, as the plaintiffs quote it | A letter of January 21, 2026 says the judgment remains unsatisfied |
What the documents show that the headlines don't
The price: three starting numbers
The court's own finding is that between 2011 and 2015 earlier owners raised the list price of a tablet from $6.74 to $17.60, and that within days of Vyera's purchase and at Shkreli's direction the price went from $17.60 to $750 on August 11, 2015. The FTC's December 2021 release and the 2024 FTC statement say $17.50, and so does the New York Attorney General. Both figures are in government documents, a dime apart, and the $13.50 widely repeated is in neither. The hike was 42.6 times the court's starting price (our arithmetic: $750 divided by $17.60).
| Item | Figure | Source |
|---|---|---|
| Offer to the rights holder, April 2015 | $60 million | S.D.N.Y. opinion |
| Price paid, closed August 7, 2015 | $55 million | S.D.N.Y. opinion |
| Daraprim annual net sales at the time | Roughly $4 million | S.D.N.Y. opinion |
| List price per tablet before and after | $17.60 to $750 (court); $17.50 to $750 (FTC) | S.D.N.Y. opinion; FTC press release |
| Average net price per tablet, about 2016 to 2019 | $228 to $305 | S.D.N.Y. opinion |
| Change in sales volume, nine months before and after | Down 66% | S.D.N.Y. opinion |
| Tablets sold a year after the hike | 200,000 to 250,000 (about one million a year market in September 2015) | S.D.N.Y. opinion |
The list price is not what was collected. After discounts, chargebacks and rebates the court puts the average net price at $228 to $305 a tablet for 2016 to 2019, about 30 to 41 percent of the $750 sticker (our arithmetic), on a market that shrank by two-thirds. The court found that he delayed the entry of generic competition for at least eighteen months, and the disgorgement is measured from that delay, not from the price itself.
How $64.6 million was built
The court did not take the price increase and multiply. It adopted a counterfactual: with generic entry as soon as the evidence supported, Vyera would have earned $67.6 million less in Daraprim revenue between October 2018 and December 2020, and would have avoided about $3 million of costs, which leaves $64.6 million (our arithmetic: $67.6 million minus $3 million). Actual revenue in the period was $130.6 million, so the order is about half of what Daraprim brought in (our arithmetic: 49.5 percent).
The order is joint and several with Vyera, subject to a set-off of what the settling defendants pay. That set-off is why the $40 million company settlement and the $64.6 million are not additive: the plaintiffs' own October 2026 brief describes the figure as "subject to offset of up to $40 million if paid by Corporate Defendants". The FTC itself could not receive any of it, because the opinion's footnote 39 says the FTC is precluded from seeking disgorgement; the money was ordered to the states.
The Second Circuit left all of it in place. It said Shkreli had raised the argument against joint and several disgorgement for the first time on appeal and declined to hear it, and that "even if this argument were not waived, it would still fail".
A lifetime ban, and what the plaintiffs first asked for
The plaintiffs' pretrial memorandum asked for a twenty-year ban. The court went to a lifetime ban, saying his "egregious, deliberate, repetitive, long-running, and ultimately dangerous illegal conduct" warranted it. The injunction covers more than running a drug company: the plaintiffs quote it as barring him from “[a]cquiring or holding an Ownership Interest in a Pharmaceutical Company”. The October 2026 contempt motion is built on that sentence. It alleges he traded the stocks of at least 60 pharmaceutical companies and asks the court to order him to divest, to pay a fine equal to his trading profits plus prejudgment interest, and to face escalating consequences. These are allegations in a motion; we found no ruling.
The forfeiture: three figures, one album
The Justice Department's sentencing release says the court ordered $7.3 million of forfeiture. Its July 2021 release calls the same judgment approximately $7.4 million. The government's own motion of November 30, 2017 asked for $7,360,450, built from $2,998,000 for the MSMB Capital count, $3,402,450 for the MSMB Healthcare count and $960,000 for the Retrophin shares count (our arithmetic confirms the sum). We could not read the order itself, so we give all three and the source of each.
The motion lists what the government wanted if the cash was not enough: $5 million held as security for the bail bond, his interest in Turing Pharmaceuticals shares, the Wu-Tang album, a second album, an Enigma machine and a painting. After the Second Circuit upheld the conviction and sentence in July 2019 and the Supreme Court declined review, the United States seized the album and sold it. The DOJ release says the contract "contains a confidentiality provision that protects information relating to the buyer and price" and that the sale completed the forfeiture. So the amount the album brought is unknown; we know only that the proceeds covered what was still owed on a judgment of about $7.4 million. We found no primary filing on later disputes over the album and say nothing about them.
The table nobody has: what Retrophin said about its founder's debts
On February 20, 2015 Retrophin filed a Form 8-K on an investigation its board had begun in September 2014 into agreements its former CEO had signed. An oversight committee of two directors concluded that several consulting agreements were really settlements of claims against his hedge funds and against him personally. These are the company's figures, not a court's:
| Category | Retrophin's disclosure | What the committee concluded |
|---|---|---|
| Consulting agreements, September 2013 to March 2014 | 612,500 shares and $400,000 in cash | Predominant purpose appears to be settling and releasing claims against the MSMB entities or him personally |
| Settlement agreements, second quarter of 2013 | About $2.2 million in cash and 11,000 shares from the company; 47,128 shares delivered by him | Settlements with investors in the MSMB entities |
| A further settlement | $300,000 in cash | Also with a former MSMB investor; purpose was to release claims against the MSMB entities and him |
| A previously undisclosed settlement | 80,000 shares delivered by him | With another former MSMB investor |
| Litigation settlements, second quarter of 2014 | About $200,000 in cash; 176,388 shares transferred directly to him | Appear to have been made to cause the transfer of shares to him |
| Repaid note, quarter ended March 31, 2013 | $900,000 repaid to an MSMB entity, plus a $575,000 payment to him | $900,000 and the payment appear to have been passed to a third party in an arbitration settlement; the $575,000 appears to have been a discretionary bonus |
| Other obligations paid or forgiven | About $1.2 million | For the primary benefit of the MSMB entities |
The board concluded on February 19, 2015 that the 2013 third-quarter 10-Q and the 2013 10-K "should no longer be relied upon". The criminal court reached its own number: the Justice Department says the settlement and sham consulting agreements caused Retrophin losses of over $10 million, and the sentencing judge found that scheme proved by a preponderance of the evidence, a lower standard than the jury's. The jury's three counts were separate: the two hedge funds and the plan to control the price and volume of Retrophin stock.
What the SEC case did and did not do
The SEC filed on December 17, 2015, the day the court records say he was arrested on the criminal charges, and closed it on February 23, 2022 with a final judgment: a permanent officer and director bar for companies with registered securities, and a $1,392,000 penalty. The judgment records that the SEC withdrew its claims for disgorgement and prejudgment interest. The bar is narrower than the FTC ban: it covers serving as an officer or director of an SEC-reporting issuer, not holding shares in one.
What this means for your money
This is the case of a manager who handled other people's money, and the records say how the money was kept from the people it belonged to. Use them as a checklist, not a verdict.
- Where did the statement come from? The Justice Department says that after trading losses he sent investors fabricated performance updates claiming big profits. A statement from the manager is not evidence of value. Ask for the account statement from an independent administrator or custodian, and for the audited financial statements of the fund.
- Compare what the manager takes with the contract. The fee terms the Justice Department quotes are a one percent management fee and a 20 percent net profit incentive allocation; it says he withdrew more than $200,000 from one fund beyond them. The partnership agreement states the fee. Add up what the statements show leaving the fund and compare.
- Who really owns the shares? In the Retrophin count the Justice Department says associates held free-trading shares as nominees and a false document hid his control. In any listed company, read the beneficial ownership table of the proxy statement and the Schedule 13D and 13G filings, and ask who else the holders are connected to.
- Related-party payments live in the 10-K. Retrophin's board found that company money paid for obligations of its founder's funds. The related-party note and the legal proceedings section are where this would have been disclosed. See what WeWork's S-1 showed about its founder for a filing where the related-party terms were in the document.
- An order is not a payment. Of about $73.8 million in orders (our arithmetic), the one document that closes an amount is the forfeiture: paid by an asset sale. The plaintiffs' October 2026 brief says he still owes the $64.6 million, quotes a 2025 writ saying he owed the SEC penalty plus interest, and quotes a January 2026 letter saying a private judgment remains unsatisfied. For what investors usually receive in other cases, compare the Madoff trustee's recoveries, our table of real-estate and private-fund fraud recoveries and what the Theranos records show.
- A ban follows the person, but your exposure does not. The court’s order of January 14, 2022 (S.D.N.Y. case 1:20-cv-00706, Document 865) bars him for life from participating in the pharmaceutical industry; the SEC final judgment of February 23, 2022 bars him from serving as an officer or director of a reporting company. If you hold a fund, a SPAC or a private deal, ask whether a manager, sponsor or director is subject to either, and check the FINRA BrokerCheck and SEC adviser records of the firm.
Do not read this as more than the court records say. The SEC and the contempt motion contain allegations; the convictions, the opinion and the SEC final judgment are rulings. This is analysis of public documents, not investment, legal or tax advice.
FAQ
Sources, read on November 20, 2026: U.S. Attorney's Office, Eastern District of New York, press releases "Martin Shkreli Sentenced to Seven Years' Imprisonment" (March 2018) and "United States Sells Unique Wu-Tang Clan Album" (updated July 27, 2021); United States v. Shkreli, 15-cr-637 (E.D.N.Y.), the government's forfeiture letter, Document 464 (November 30, 2017); FTC et al. v. Shkreli, 1:20-cv-00706 (S.D.N.Y.), Opinion and Order, Document 865 (January 14, 2022); Second Circuit summary order No. 22-728 (January 23, 2024); FTC press releases of December 7, 2021 and October 13, 2026 and statement of January 23, 2024; New York Attorney General press releases of January 14, 2022 and January 23, 2024; the plaintiffs' memorandum of law in support of the order to show cause, S.D.N.Y. 1:20-cv-00706 (October 2026); SEC Litigation Release No. 25337 and the final judgment in SEC v. Shkreli, 15-cv-7175 (E.D.N.Y.), Document 55 (February 23, 2022); Retrophin, Inc. Form 8-K filed February 20, 2015, accession 0001193125-15-056286 (Retrophin, now Travere Therapeutics, CIK 1438533).